Abattis Bioceuticals Corp. (ATTBF)

[GreenBrickRoad]

I'd guess William Panenka sits in on product and marketing brainstorming sessions and helps verify the clinical and scientific value to what other directors propose. I don't doubt his input is useful.. just seems like he's shamelessly in it for the short-term.

He also dumped 100K's of shares last year too.. Honestly, this is the type of situation where I'm wouldn't be surprised.. in fact, more like I'm almost expecting.. to hear an announcement within a couple months announcing his resignation and "moving on" to blah, blah, blah...

From 11/2/16 PR...

Dr. Panenka received his M.D. and M.Sc. from the University of Calgary in Canada. His M.Sc was basic science-focused utilizing Western Blotting, PCR, in-situ hybridization and other wet lab techniques. He completed residencies in both psychiatry and neurology at the University of British Columbia in Vancouver, Canada.

In 2011 Dr. Panenka began a research fellowship focusing on the mental and physical health, as well as the brain imaging correlates of drug use and addictions. In 2012, he became a research fellow at Harvard University and was competitively recruited to the University of British Columbia in 2013 as an assistant professor in psychiatry. His main focus is addiction and traumatic brain injury, with multiple basic science and clinical collaborations nationally and internationally.

Dr. Panenka is currently a co-investigator on several clinical studies involving Cannabis, focusing on the effects of THC and CBD on psychosis, mood and anxiety. In collaboration with a local biotech start-up company, his team at UBC was recently awarded a MITACS industry-academic partnership grant to partially fund this research.

According to Rene David, CFO and acting CEO of Abattis Bioceuticals, "We are extremely pleased Dr. Panenka has agreed to join our board as an independent director. He provides us with a wealth of knowledge and experience as a clinician, researcher and professor and welcome his input with respect to our nutraceutical product lines and controlled substances testing facility. We look forward to his guidance as Abattis and subsidiaries navigate the legal cannabis industry."